Roel Arthur Rozendaal1, Ben J Mijnheer2, Marcel van Herk2, Anton Mans2. 1. Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: r.rozendaal@nki.nl. 2. Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Abstract
PURPOSE: To relate the results of γ-analysis and dose-volume histogram (DVH) analysis of the PTV for detecting dose deviations with in vivo dosimetry for two treatment sites. METHODS AND MATERIALS: In vivo 3D dose distributions were reconstructed for 722 fractions of 200 head-and-neck (H&N) VMAT treatments and 183 fractions of 61 lung IMRT plans. The reconstructed and planned dose distributions in the PTV were compared using (a) the γ-distribution and (b) the differences in D2, D50 and D98 between the two dose distributions. Using pre-defined tolerance levels, all fractions were classified as deviating or not deviating by both methods. The mutual agreement, the sensitivity and the specificity of the two methods were compared. RESULTS: For lung IMRT, the classification of the fractions was nearly identical for γ- and DVH-analyses of the PTV (94% agreement) and the sensitivity and specificity were comparable for both methods. Less agreement (80%) was found for H&N VMAT, while γ-analysis was both less sensitive and less specific. CONCLUSIONS: DVH- and γ-analyses perform nearly equal in finding dose deviations in the PTV for lung IMRT treatments; for H&N VMAT treatments, DVH-analysis is preferable. As a result of this study, a smooth transition to using DVH-analysis clinically for detecting in vivo dose deviations in the PTV is within reach.
PURPOSE: To relate the results of γ-analysis and dose-volume histogram (DVH) analysis of the PTV for detecting dose deviations with in vivo dosimetry for two treatment sites. METHODS AND MATERIALS: In vivo 3D dose distributions were reconstructed for 722 fractions of 200 head-and-neck (H&N) VMAT treatments and 183 fractions of 61 lung IMRT plans. The reconstructed and planned dose distributions in the PTV were compared using (a) the γ-distribution and (b) the differences in D2, D50 and D98 between the two dose distributions. Using pre-defined tolerance levels, all fractions were classified as deviating or not deviating by both methods. The mutual agreement, the sensitivity and the specificity of the two methods were compared. RESULTS: For lung IMRT, the classification of the fractions was nearly identical for γ- and DVH-analyses of the PTV (94% agreement) and the sensitivity and specificity were comparable for both methods. Less agreement (80%) was found for H&N VMAT, while γ-analysis was both less sensitive and less specific. CONCLUSIONS: DVH- and γ-analyses perform nearly equal in finding dose deviations in the PTV for lung IMRT treatments; for H&N VMAT treatments, DVH-analysis is preferable. As a result of this study, a smooth transition to using DVH-analysis clinically for detecting in vivo dose deviations in the PTV is within reach.
Authors: Maria D Falco; Stefano Giancaterino; Andrea De Nicola; Nico Adorante; Ramon Gimenez De Lorenzo; Monica Di Tommaso; Annamaria Vinciguerra; Marianna Trignani; Francesca Perrotti; Albina Allajbej; Andrea Fidanzio; Francesca Greco; Mattia Grusio; Domenico Genovesi; Angelo Piermattei Journal: Technol Cancer Res Treat Date: 2018-01-01
Authors: S B Lim; C J Tsai; Y Yu; P Greer; T Fuangrod; K Hwang; S Fontenla; F Coffman; N Lee; D M Lovelock Journal: Technol Cancer Res Treat Date: 2019-01-01
Authors: Seng Boh Lim; Nancy Lee; Kaveh Zakeri; Peter Greer; Todsaporn Fuangrod; Frederick Coffman; Laura Cerviño; D Michael Lovelock Journal: Technol Cancer Res Treat Date: 2021 Jan-Dec